Q1 2024 Earnings Forecast for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Issued By Zacks Small Cap

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings per share estimates for Brainstorm Cell Therapeutics in a report issued on Thursday, April 11th. Zacks Small Cap analyst D. Bautz expects that the biotechnology company will post earnings per share of ($0.07) for the quarter. The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($0.47) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.07) EPS and FY2026 earnings at ($0.24) EPS.

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They set a “sell” rating for the company.

Brainstorm Cell Therapeutics Trading Down 3.9 %

NASDAQ:BCLI opened at $0.53 on Monday. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $3.37. The company has a market cap of $36.02 million, a price-to-earnings ratio of -1.29 and a beta of 0.27. The stock has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.31.

Institutional Trading of Brainstorm Cell Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Kingswood Wealth Advisors LLC bought a new position in Brainstorm Cell Therapeutics in the first quarter worth about $46,000. GTS Securities LLC purchased a new stake in shares of Brainstorm Cell Therapeutics during the third quarter worth about $41,000. Wells Fargo & Company MN grew its stake in shares of Brainstorm Cell Therapeutics by 50.6% during the second quarter. Wells Fargo & Company MN now owns 37,354 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 12,546 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Brainstorm Cell Therapeutics during the second quarter worth about $139,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Brainstorm Cell Therapeutics during the second quarter worth about $426,000. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.